Sign up to save your podcasts
Or
Share FDA approves second Alzheimer’s treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA approves second Alzheimer’s treatment
On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By POLITICO
4.7
453453 ratings
On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like POLITICO's Pulse Check
View all
POLITICO's Off Message
609 Listeners
The Conversation with Dasha Burns
1,523 Listeners
The Playbook Podcast
707 Listeners
The Daily
113,121 Listeners
Power Play
963 Listeners
Women Rule
307 Listeners
Up First from NPR
56,944 Listeners
Brussels Playbook Podcast
108 Listeners
What the Health? From KFF Health News
498 Listeners
POLITICO Money
206 Listeners
FT News Briefing
684 Listeners
Fiction - Comedy Fiction
6,446 Listeners
POLITICO Energy
141 Listeners
POLITICO Tech
386 Listeners
Westminster Insider
41 Listeners
POLITICO Berlin Playbook
12 Listeners
The Headlines
747 Listeners